Barbara Jungwirth is an experienced freelance journalist, writer, and translator who has been reporting on HIV for TheBody and TheBodyPro since 2002. Specializing in technical summaries of published and presented research on HIV and related topics, Barbara has been the primary author of TheBodyPro's "This Week in HIV Research" series since 2014.
Latest by Barbara Jungwirth
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Doctors contemplate the role of housing in health care as people with HIV grow older, but are often poor.
Addiction needs to be addressed by prevention and treatment, but policy makers need skin in the game too.
Feb. 20, 2020: Protease inhibitors and heart attack risk; HIV status and pericardial adipose tissue volume; cardiovascular risk profiles on TDF vs. TAF; hemostatic profiles in older people living with HIV.
Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.
HVTN 702 is but one of many vaccine trials underway, researchers note.
Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Jan. 23, 2020: Neurocognitive benefits of cannabis use; how unquantifiable HIV in CSF correlates to executive function; updated findings on efavirenz and microcephaly; cost-efficacy of a specialized HIV care coordination team.